Biocon Limited · NSE:BIOCON
Biocon — Merger or Acquisition (February 2022)
12 slides from Biocon's merger presentation, Mar 1, 2022
Slide 1: Cover letter to stock exchanges
Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 www.biocon.com February 28, 2022 To To The Secretary The Secretary BSE Limited National Stock Exchange of India Limited Department of Corporate Services Corpora
Slide 2: Biocon Biologics to acquire Viatris' Biosimilars Business
Biocon Biologics to acquire Viatris’ Biosimilars Business 28 February 2022
Slide 3: Safe Harbor Statement
Safe Harbor Statement Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking s
Slide 4: Biocon has consistently unlocked value over four decades
Biocon has consistently unlocked value over four decades Biocon has benefited from transformational moves every decade 1978 1989 1993 1998 2004 2007 2009 2015 2022 Acquisition of Unilever Mylan BBL to Biocon stake Divestment partnership acquire founded as Unilever plc Syngene Biocon Syngene of enzym
Slide 5: Mapping Biocon Biologics capabilities as a biosimilars company
Mapping Biocon Biologics capabilities as a biosimilars company Emerging Markets Developed Markets PRODUCT DEVELOPMENT ✓ ✓ Biosimilar Value Chain CLINICAL TRIALS ✓ ✓ R E G U L AT O R Y ✓ M AN U FAC T U R I N G ✓ ✓ S U P P LY C H A I N ✓ C O M M E R C I A L I Z AT I O N ✓ 4
Slide 6: Viatris' biosimilars business adds financial depth and commercial capabilities
Viatris’ biosimilars business adds financial depth and commercial capabilities 1 Revenue EBITDA BBL to realize full revenue and profits Financial $1.1b | $250m from all its collaboration programs Viatris Biosimilars CY23 estimate1 2 Commercialization, Supply Chain and Operational Regulatory capabili
Slide 7: Considerations to Viatris
Considerations to Viatris 1 Cash Payment of $2b at Closing ($50m payment from Viatris for capex funding) $1,950m 2 Compulsorily Convertible Preference Shares (represents an equity stake of at least 12.9%) $1,000m Total considerations at $2.3b in cash and 3 Deferred consideration (payment due in FY25
Slide 8: Financing the acquisition
Financing the acquisition 1 Payment at Closing $1,950m Combination of equity and debt A Equity commitment received $800m Well positioned to fund the acquisition B Debt commitment received $1,800m 2 Deferred Considerations $335m Primarily through cash generated from the business Strictly Confidential
Slide 9: Biocon Biologics to be a fully integrated global biosimilars company
Biocon Biologics to be a fully integrated global biosimilars company… CURRENT POST ACQUISITION Emerging Markets Developed Markets Global markets PRODUCT DEVELOPMENT ✓ ✓ ✓ Biosimilar Value Chain CLINICAL TRIALS ✓ ✓ ✓ R E G U L AT O R Y ✓ ✓ M AN U FAC T U R I N G ✓ ✓ ✓ S U P P LY C H A I N ✓ ✓ C O
Slide 10: A comprehensive portfolio providing scale and future growth
…with a comprehensive portfolio providing scale and future growth Today < 2 years 2-4 years >4 years - Pegfilgrastim - Bevacizumab (US) - Aflibercept - Pertuzumab - Trastuzumab - Aspart (US) - Two undisclosed - Glargine 300 IU - Bevacizumab (EU) - Adalimumab (US) programs - Seven undisclosed - Glarg
Slide 11: Building an organization for the next decade
Building an organization for the next decade Key investment highlights 1 Fully integrated global biosimilars company (lab to market) 2 Strong commercial presence in global markets 3 Comprehensive portfolio of biosimilars and vaccines 4 Global scale biologics manufacturing capacity 5 Experienced mana
Slide 12: Q&A
Q&A gS Biocon Biologics